MARKET

STRO

STRO

Sutro Biopharma
NASDAQ
8.87
-0.02
-0.17%
After Hours: 8.87 0 0.00% 19:30 10/27 EDT
OPEN
8.87
PREV CLOSE
8.89
HIGH
9.14
LOW
8.44
VOLUME
453.24K
TURNOVER
--
52 WEEK HIGH
43.85
52 WEEK LOW
7.15
MARKET CAP
147.07M
P/E (TTM)
-0.5121
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at STRO last week (1019-1023)?
Weekly Report · 1d ago
Analysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO), Lucid Diagnostics (LUCD) and MIRA Pharmaceuticals, Inc. (MIRA)
TipRanks · 2d ago
Sutro’s New Phase 1 Cancer Study Puts STRO-006 in the Spotlight
TipRanks · 4d ago
Sutro Biopharma doses first patient in STRO-006 trial
TipRanks · 6d ago
Sutro Biopharma Doses First Patient In Its Phase 1 Trial Of STRO-006 In Patients With Range Of Solid Tumors; Initial Clinical Data Expected In H2 2027
Benzinga · 6d ago
Analysts’ Top Healthcare Picks: Eli Lilly & Co (LLY), Vir Biotechnology (VIR)
TipRanks · 10/19 12:20
Weekly Report: what happened at STRO last week (1012-1016)?
Weekly Report · 10/19 09:20
Analyst Maintains Buy on Sutro Biopharma, Reaffirming $50 Price Target on Differentiated ADC Platform
TipRanks · 10/16 10:36
More
About STRO
Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.

Webull offers Sutro Biopharma Inc stock information, including NASDAQ: STRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STRO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading STRO stock methods without spending real money on the virtual paper trading platform.